BioMarin Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
BioMarin Pharmaceutical's earnings have been declining at an average annual rate of -11.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9% per year. BioMarin Pharmaceutical's return on equity is 6%, and it has net margins of 11.7%.
Key information
-11.3%
Earnings growth rate
-12.3%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 9.0% |
Return on equity | 6.0% |
Net Margin | 11.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioMarin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,753 | 322 | 1,033 | 33 |
30 Jun 24 | 2,588 | 257 | 995 | 0 |
31 Mar 24 | 2,472 | 205 | 938 | 0 |
31 Dec 23 | 2,419 | 168 | 923 | 0 |
30 Sep 23 | 2,311 | 147 | 856 | 541 |
30 Jun 23 | 2,235 | 100 | 857 | 0 |
31 Mar 23 | 2,173 | 72 | 847 | 0 |
31 Dec 22 | 2,096 | 142 | 831 | 0 |
30 Sep 22 | 2,008 | 84 | 826 | 0 |
30 Jun 22 | 1,912 | 54 | 792 | 0 |
31 Mar 22 | 1,880 | 39 | 780 | 0 |
31 Dec 21 | 1,846 | -64 | 759 | 0 |
30 Sep 21 | 1,849 | 16 | 737 | 0 |
30 Jun 21 | 1,917 | 837 | 733 | 0 |
31 Mar 21 | 1,844 | 795 | 725 | 0 |
31 Dec 20 | 1,860 | 854 | 738 | 0 |
30 Sep 20 | 1,863 | 852 | 730 | 0 |
30 Jun 20 | 1,847 | 122 | 721 | 0 |
31 Mar 20 | 1,805 | 114 | 706 | 0 |
31 Dec 19 | 1,704 | -24 | 681 | 0 |
30 Sep 19 | 1,603 | -43 | 657 | 0 |
30 Jun 19 | 1,533 | -110 | 636 | 0 |
31 Mar 19 | 1,519 | -90 | 628 | 0 |
31 Dec 18 | 1,491 | -77 | 604 | 0 |
30 Sep 18 | 1,496 | -125 | 600 | 0 |
30 Jun 18 | 1,439 | -125 | 582 | 0 |
31 Mar 18 | 1,383 | -145 | 573 | 0 |
31 Dec 17 | 1,314 | -117 | 554 | 0 |
30 Sep 17 | 1,255 | -156 | 537 | 0 |
30 Jun 17 | 1,201 | -181 | 525 | 0 |
31 Mar 17 | 1,184 | -563 | 491 | 0 |
31 Dec 16 | 1,117 | -630 | 477 | 0 |
30 Sep 16 | 1,045 | -471 | 441 | 0 |
30 Jun 16 | 974 | -524 | 416 | 0 |
31 Mar 16 | 924 | -187 | 408 | 0 |
31 Dec 15 | 890 | -172 | 402 | 0 |
30 Sep 15 | 892 | -310 | 385 | 0 |
30 Jun 15 | 859 | -212 | 366 | 0 |
31 Mar 15 | 801 | -163 | 332 | 0 |
31 Dec 14 | 749 | -134 | 299 | 0 |
30 Sep 14 | 666 | -126 | 274 | 0 |
30 Jun 14 | 627 | -187 | 262 | 0 |
31 Mar 14 | 572 | -175 | 244 | 0 |
31 Dec 13 | 548 | -176 | 235 | 0 |
Quality Earnings: BM8 has high quality earnings.
Growing Profit Margin: BM8's current net profit margins (11.7%) are higher than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BM8 has become profitable over the past 5 years, growing earnings by -11.3% per year.
Accelerating Growth: BM8's earnings growth over the past year (119.2%) exceeds its 5-year average (-11.3% per year).
Earnings vs Industry: BM8 earnings growth over the past year (119.2%) exceeded the Biotechs industry -18.2%.
Return on Equity
High ROE: BM8's Return on Equity (6%) is considered low.